| 摘要 |
<p>The present invention relates to pharmaceutical uses of c-Yes for differentiation therapy of cancer stem cells. More specifically, the c-Yes: has drastically higher expression amount in CD133-positive cancer stem cells than CD133-negative cancer stem cells; and inhibits tolerance or recurrence against chemotherapy or radiotherapy by inhibiting proliferation of the cancer stem cells. Also the cancer stem cells are promoted to be differentiated into cancer cells in exhaustion of the c-Yes; therefore the c-Yes prevents or treats CD133-positive cancer.</p> |
